Why Is Zoetis (ZTS) Up 8.1% Since Last Earnings Report?

It has been about a month since the last earnings report for Zoetis (ZTS). Shares have added about 8.1% in that time frame, outperforming the S&P 500.

Will the recent positive trend continue leading up to its next earnings release, or is Zoetis due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.

How Have Estimates Been Moving Since Then?

It turns out, estimates revision have trended downward during the past month.

VGM Scores

At this time, Zoetis has a nice Growth Score of B, though it is lagging a bit on the Momentum Score front with a C. Following the exact same course, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.

Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.

Outlook

Estimates have been trending downward for the stock, and the magnitude of these revisions looks promising. Notably, Zoetis has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.

Performance of an Industry Player

Zoetis belongs to the Zacks Medical - Drugs industry. Another stock from the same industry, Recursion Pharmaceuticals (RXRX), has gained 17.2% over the past month. More than a month has passed since the company reported results for the quarter ended March 2025.

Recursion Pharmaceuticals reported revenues of $14.74 million in the last reported quarter, representing a year-over-year change of +6.9%. EPS of -$0.50 for the same period compares with -$0.39 a year ago.

Recursion Pharmaceuticals is expected to post a loss of $0.36 per share for the current quarter, representing a year-over-year change of +10%. Over the last 30 days, the Zacks Consensus Estimate has changed +7.8%.

The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Recursion Pharmaceuticals. Also, the stock has a VGM Score of F.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research